Key Takeaways
- Xbrane Biopharma has revealed 21 October as the latest FDA action date for its proposed biosimilar to Lucentis (ranibizumab).
Xbrane Biopharma has provided an update on its long-gestating filing for a biosimilar version of Genentech’s Lucentis (ranibizumab) in the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?